Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety and Efficacy Evaluation Study of Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC

NCT06739928 is registered in ClinicalTrials.gov with Guangzhou Institute of Respiratory Disease as lead sponsor.

NCT NCT06739928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06739928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety and Efficacy Evaluation Study of Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC
Lead sponsor
Guangzhou Institute of Respiratory Disease
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2025
Completion date
December 30, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer extensive stage